Abstract
Background
D-index is a recently established clinical tool for assessing neutropenia severity. This study examined whether the D-index can predict the onset of various infections in patients with febrile neutropenia (FN).
Methods
We retrospectively investigated FN events in consecutive patients aged < 65 years who were treated for newly diagnosed acute myeloid leukemia at our institution. We collected data on all FN events during chemotherapy and evaluated the association of FN severity with infectious events. Results: This study included 35 patients (18 women and 17 men; median age, 51 years [range 18–65 years]) with 122 FN events. The response rate to induction chemotherapy was 60% (21/35), and all but one patient survived the treatment. The D-index did not predict FN onset. However, in multivariate analysis, high-dose cytarabine and total D-index were statistically significant explanatory factors for microbiological-proven infections. In addition, multivariate analysis showed that diabetes mellitus is the only risk factor for FN onset. Furthermore, older age, consolidation therapy, and cumulative D-index (c-D-index) were risk factors for prolonged FN. The FN period was the longest in patients with respiratory infections.
Conclusion
The D-index did not predict the onset of infection. However, FN duration might be prolonged during consolidation therapy in elderly patients with diabetes mellitus, and it is important to manage respiratory infections. These findings indicate the c-D-index is a useful tool to predict prolonged FN.
Similar content being viewed by others
Data Availability
The datasets used and analyzed in the present study are available from the corresponding author upon reasonable request.
Abbreviations
- AML:
-
Acute myeloid leukemia
- c-D-index:
-
Cumulative D-index
- ECOG:
-
Eastern Cooperative Oncology Group
- FAB:
-
French–American–British
- FN:
-
Febrile neutropenia
- JALSG:
-
Japan Adult Leukemia Study Group
- L-index:
-
Lymphocyte index
- PS:
-
Performance status
References
Freifeld AG, Bow EJ, Sepkowitz KA et al. (2011) Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52:427–431
Portugal RD, Garnica M, Nucci M (2009) Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol 27:3849–3854
Kimura S, Oshima K, Sato K et al. (2010) Retrospective evaluation of the area over the neutrophil curve index to predict early infection in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transpl 16:1355–1361
Kimura S, Wada H, Ishihara Y et al. (2014) D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine. Hematology 19:107–112
Aoki J, Tsubokura M, Kakihana K et al. (2014) The predictive value for pulmonary infection by area over the neutrophil curve (D-index) in patients who underwent reduced intensity hematopoietic stem cell transplantation. Pathol Oncol Res 20:879–883
Ishihara Y, Kimura S, Akahoshi Y et al. (2016) Impact of D-index and L-index on pulmonary infection in induction chemotherapy for acute lymphoblastic leukemia and lymphoblastic lymphoma. Hematology 21:19–25
Sakamaki H, Miyawaki S, Ohtake S et al. (2010) Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study. Int J Hematol 91:284–292
Ohtake S, Miyawaki S, Fujita H et al. (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 117:2358–2365
Radfar M, Faghihi T, Hadjibabaie M et al. (2015) Impact of preexisting diabetes mellitus on transplantation outcomes in hematopoietic stem cell transplantation. Endocr Res 40:20–24
Lynn JJ, Chen KF, Weng YM et al. (2013) Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department. Hematol Oncol 31:189–196
Takenaka Y, Cho H, Yamamoto M et al. (2013) Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer. Support Care Cancer 21:2861–2868
Bellesso M, Costa SF, Pracchia LF et al. (2011) Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies. Ann Hematol 90:455–462
de Naurois J, Novitzky-Basso I, Gill MJ et al. ESMO Guidelines Working Group (2010) Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 21(Suppl 5):v252–6
Schaich M, Parmentier S, Kramer M et al. (2013) High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol 31:2094–2102
Wang L, Hu J, Sun Y et al. (2016) Does high-dose cytarabine cause more fungal infection in patients with acute myeloid leukemia undergoing consolidation therapy: a Multicenter, Prospective, Observational Study in China. Medicine (Baltimore) 95:e2560
Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39:S32–S37
Funding
The authors declare that there are no funding sources to disclose concerning to this study, which was supported by internal funding.
Author information
Authors and Affiliations
Contributions
OI and HK managed the patient cases, contributed to the literature search, and wrote the manuscript. YHK made substantial contributions to the concept and design of this report. MU qualified the patient data, suggested important intellectual content. YHK and MU took part in critical discussions. NK was involved in supervision of the manuscript and managed the research. All authors approved the final version of the manuscript.
Corresponding author
Ethics declarations
Ethics approval
Institutional review board approved the clinical study and submission of medical literature.
Ethics, consent, and permissions
We have obtained consent to participate under our institutional review board.
Consent to publish
We have obtained consent to publish from the participant.
Conflict of interest
The authors declare that they have no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kubo, H., Imataki, O., Kubo, Y.H. et al. c-D-index is a risk factor for prolonged febrile neutropenia during chemotherapy in patients with acute myeloid leukemia. Int J Clin Oncol 24, 590–595 (2019). https://doi.org/10.1007/s10147-018-01384-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-018-01384-9